Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 46454 results
AbbVie enters into license deal with C2N Diagnostics for Alzheimer's disease therapy
By PBR Staff Writer
US-based AbbVie and C2N Diagnostics, a protein diagnostic and therapeutic discovery firm, have collaborated for the development and commercialization of a portfolio of anti-tau antibodies to treat Alzheimer's disease (AD) and other neurological disorders.
News
ImmunoCellular, PharmaCell partner for European production of cancer immunotherapy ICT-107
By PBR Staff Writer
US-based ImmunoCellular Therapeutics has entered into an agreement with Dutch contract manufacturing organisation (CMO) PharmaCell to offer contract manufacturing services for the European production of a dendritic cell-based cancer immunotherapy, ICT-107, being developed as a potential treatment for glioblastoma (GBM).
News
Lilly, Hanmi to develop BTK inhibitor to treat autoimmune diseases
By PBR Staff Writer
Eli Lilly and Company has entered into an exclusive license and collaboration agreement with Hanmi Pharmaceutical to develop and commercialize the latter's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, to treat autoimmune and other diseases.
News
MedImmune, FAPESP to identify new early research projects in Brazil
By PBR Staff Writer
AstraZeneca's global biologics R&D arm MedImmune has entered into a new five-year scientific and technological cooperation agreement with the São Paulo Research Foundation (FAPESP) to advance research and the scientific and technological development of the Brazilian state of São Paulo.
News
AstraZeneca, Daiichi to jointly commercialize constipation drug Movantik in US
By PBR Staff Writer
AstraZeneca has entered into a co-commercialization agreement with the US unit of Daiichi Sankyo for distribution of its constipation drug, Movantik (naloxegol), a first-in-class once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA).
News
Genmab Holding buys iDD Biotech's pre-clinical stage antibodies and related patents
By PBR Staff Writer
Genmab Holding has entered into an agreement to acquire pre-clinical stage antibodies and related patents from iDD Biotech.
News
Lexicon and Ipsen to commercialize telotristat etiprate in Canada
By PBR Staff Writer
US-based biopharmaceutical firm Lexicon and France's Ipsen have expanded their licensing and commercialization agreement to commercialize telotristat etiprate in Canada for the treatment of carcinoid syndrome.
News
Vertex's Kalydeco gets FDA aapproval for children with cystic fibrosis
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted approval for Vertex Pharmaceuticals' Kalydeco for use in children aged two to five years with cystic fibrosis (CF).
News
NantWorks, Sorrento to discover and develop new anti-cancer immunotherapies
By PBR Staff Writer
NantWorks and Sorrento Therapeutics have entered into a binding agreement for the discovery and development of new anti-cancer immunotherapies.
News
Pharmalink buys Synartro's product candidate to treat inflammation associated with osteoarthritis
By PBR Staff Writer
Swedish specialty pharmaceutical firm Pharmalink acquired a new therapeutic product candidate from Synartro, a research and development (R&D) company, to treat inflammation associated with osteoarthritis.
News
Selten's PAH treatment tacrolimus gets FDA orphan drug status
By PBR Staff Writer
US-based biopharmaceutical firm Selten Pharma has received orphan drug designation from the US Food & Drug Administration (FDA) for tacrolimus (SPI-026), an investigational Bone morphogenetic protein receptor type II (BMPR2) pathway activator for pulmonary arterial hypertension (PAH).
News
AstraZeneca reports positive results from PT003 Phase III PINNACLE trials in COPD
By PBR Staff Writer
AstraZeneca has reported positive top-line results from the Phase III PINNACLE program of PT003, a twice-daily fixed-dose combination of glycopyrronium and formoterol fumarate, to improve lung function in patients with chronic obstructive pulmonary disease (COPD).
News
GlaxoSmithKline, Johnson & Johnson invest in $100m new Alzheimer's R&D project
By PBR Staff Writer
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) have made investments in a new global fund that will support research to help find new ways to address the rising threat posed by dementia and Alzheimer’s disease.
News
Cloud Pharma, UF Department of Medicine to accelerate development of new cancer inhibitors
By PBR Staff Writer
US-based Cloud Pharmaceuticals and the University of Florida Department of Medicine have entered into an academic collaboration to rapidly design and develop new drugs to inhibit the reproduction of cancer cells.
News
Celldex, Roche to evaluate varlilumab and MPDL3280A combination in renal cell carcinoma
By PBR Staff Writer
Celldex Therapeutics has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of the combination of varlilumab and MPDL3280A (anti-PDL1) in a Phase I/II trial to treat renal cell carcinoma.
News
136-150 of 46454 results